NVP-13

N/A

Report date: 2026/03/31 20:00:21

NME

Base Information

Drug NameNVP-13

Drug Alias NameBiAgilTGFbRII targeting ASOs (University Hospital Regensburg/Covance)TGFbRII targeting antisense oligonucleotides (University Hospital Regensburg/Covance)NVP-13

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionTransforming growth factor beta receptor 2 modulators

TargetsTransforming growth factor beta receptor 2

Therapy Area/IndicationsAmyotrophic Lateral Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Regensburg

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Regensburg

Inactive CompaniesN/A

Active IndicationsAmyotrophic Lateral Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A